Volume 178, Issue Supplement_1
November 1998
ISSN 0022-1899
EISSN 1537-6613
Issue navigation
Volume 178, Issue Supplement_1, November 1998
The Third International Conference on the Varicella-Zoster Virus
Foreword: The Third International Conference on the Varicella-Zoster Virus
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Page S1, https://doi.org/10.1086/514253
Dedication
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Page Siii, https://doi.org/10.1086/514252
Basic Virology and Pathogenesis
Varicella-Zoster Virus Glycoprotein gE: Endocytosis and Trafficking of the Fc Receptor
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S2–S6, https://doi.org/10.1086/514255
Intracellular Transport of Varicella-Zoster Glycoproteins
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S7–S12, https://doi.org/10.1086/514268
Baculovirus Expression, Purification, and Properties of Varicella-Zoster Virus gE, gI, and the Complex They Form
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S13–S15, https://doi.org/10.1086/514256
Regulated Nuclear Localization of the Varicella-Zoster Virus Major Regulatory Protein, IE62
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S16–S21, https://doi.org/10.1086/514263
Analysis of the Glycoproteins I and E of Varicella-Zoster Virus (VZV) using Deletional Mutations of VZV Cosmids
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S22–S26, https://doi.org/10.1086/514277
Anatomy of the Varicella-Zoster Virus Open-Reading Frame 4 Promoter
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S27–S33, https://doi.org/10.1086/514273
The Varicella-Zoster Virus (VZV) Open-Reading Frame 29 Protein Acts as a Modulator of a Late VZV Gene Promoter
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S34–S38, https://doi.org/10.1086/514276
Isolation and Utilization of Human Dendritic Cells from Peripheral Blood to Assay an In Vitro Primary Immune Response to Varicella-Zoster Virus Peptides
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S39–S42, https://doi.org/10.1086/514258
Varicella-Zoster Virus IE63, a Virion Component Expressed during Latency and Acute Infection, Elicits Humoral and Cellular Immunity
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S43–S47, https://doi.org/10.1086/514259
Evidence of Latent Varicella-Zoster Virus in Rat Dorsal Root Ganglia
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S48–S51, https://doi.org/10.1086/514261
Clinical Aspects, Treatment, and Prevention of Chickenpox
Adult Susceptibility to Varicella in the Tropics Is a Rural Phenomenon Due to the Lack of Previous Exposure
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S52–S54, https://doi.org/10.1086/514262
Single Amino Acid Change in DNA Polymerase Is Associated with Foscarnet Resistance in a Varicella-Zoster Virus Strain Recovered from a Patient with AIDS
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S55–S57, https://doi.org/10.1086/514257
Cost of Varicella in France: A Study in Day Care Centers
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S58–S63, https://doi.org/10.1086/514275
Polymerase Chain Reaction and Restriction Fragment Length Polymorphism Analysis of Varicella-Zoster Virus Isolates from the United States and Other Parts of the World
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S64–S66, https://doi.org/10.1086/514267
Clinical Aspects, Treatment, and Prevention of Zoster and Postherpetic Neuralgia
Racial and Psychosocial Risk Factors for Herpes Zoster in the Elderly
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S67–S70, https://doi.org/10.1086/514254
The Identification of Risk Factors Associated with Persistent Pain following Herpes Zoster
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S71–S75, https://doi.org/10.1086/514274
Postherpetic Neuralgia: Impact of Famciclovir, Age, Rash Severity, and Acute Pain in Herpes Zoster Patients
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S76–S80, https://doi.org/10.1086/514260
Treatment of Acute Herpes Zoster: Effect of Early (< 48 h) versus Late (48–72 h) Therapy with Acyclovir and Valaciclovir on Prolonged Pain
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S81–S84, https://doi.org/10.1086/514271
Cost Effectiveness of Newer Antiviral Agents for Herpes Zoster: Is the Evidence Spotty?
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S85–S90, https://doi.org/10.1086/514270
Postherpetic Neuralgia: The Importance of Preventing This Intractable End-Stage Disorder
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S91–S94, https://doi.org/10.1086/514269
Cytokine Production in Varicella-Zoster Virus—Stimulated Cultures of Human Blood Lymphocytes
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S95–S98, https://doi.org/10.1086/514266
A Dose-Response Study of a Live Attenuated Varicella-Zoster Virus (Oka Strain) Vaccine Administered to Adults 55 Years of Age and Older
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S99–S103, https://doi.org/10.1086/514265
Cellular Immunity to Varicella-Zoster Virus in Patients with Major Depression
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S104–S108, https://doi.org/10.1086/514272
Use of a Live Attenuated Varicella Vaccine to Boost Varicella-Specific Immune Responses in Seropositive People 55 Years of Age and Older: Duration of Booster Effect
The Journal of Infectious Diseases, Volume 178, Issue Supplement_1, November 1998, Pages S109–S112, https://doi.org/10.1086/514264
